Dermata Therapeutics, Inc. - Equity Warrant

Introduction

This page provides a comprehensive analysis of the known insider trading history of David F Hale. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David F Hale has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:DRMA / Dermata Therapeutics, Inc. Director 80,957
US:ONCT / Oncternal Therapeutics, Inc. Director 29,673
US:BIOC / Biocept Inc Director 796
US:CNAT / Conatus Pharmaceuticals Inc. Director 45,000
US:SNTS / Santarus, Inc Director 0
US:SOMX / Somaxon Pharmaceuticals, Inc. Director 0
Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David F Hale. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases DRMAW / Dermata Therapeutics, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-08-17 DRMA HALE DAVID F 35,714 2,613 78 1500

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DRMAW / Dermata Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Sales DRMAW / Dermata Therapeutics, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DRMAW / Dermata Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Purchases HSTOQ / Histogen Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2013-07-30 CNAT HALE DAVID F 2,588 11.0000 2,588 11.0000 28,468 164

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HSTOQ / Histogen Inc. Insider Trades
Insider Sales HSTOQ / Histogen Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HSTOQ / Histogen Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David F Hale as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-23 2025-01-23 4 DRMA Dermata Therapeutics, Inc.
Common Stock
A - Award 78,741 80,957 3,553.29
2024-02-27 2024-02-23 4 ONCT Oncternal Therapeutics, Inc.
Common Stock
P - Purchase 266 29,673 0.90 9.04 2,405 268,244
2024-02-27 2024-02-23 4 ONCT Oncternal Therapeutics, Inc.
Common Stock
P - Purchase 714 714 9.04 6,455 6,455
2022-10-07 2022-10-06 4 DRMA Dermata Therapeutics, Inc.
Common Stock
A - Award 30,155 75,720 66.18
2022-07-08 2022-07-07 4 DRMA Dermata Therapeutics, Inc.
Common Stock
A - Award 26,441 45,565 138.26
2022-04-08 2022-04-07 4 DRMA Dermata Therapeutics, Inc.
Common Stock
A - Award 15,466 19,124 422.80
2022-02-11 2021-10-01 5 ONCT Oncternal Therapeutics, Inc.
Common Stock
G - Gift -125,000 588,152 -17.53
2022-01-05 2022-01-03 4 DRMA Dermata Therapeutics, Inc.
Stock Option (right to buy)
A - Award 5,000 5,000
2021-12-10 2021-12-09 4 BIOC BIOCEPT INC
Common Stock
S - Sale -71 796 -8.19 4.07 -289 3,237
2021-12-10 2021-12-09 4 BIOC BIOCEPT INC
Common Stock
S - Sale -11 101 -9.82 4.07 -45 411
2021-12-10 2021-12-09 4 BIOC BIOCEPT INC
Common Stock
S - Sale -363 3,114 -10.44 4.06 -1,474 12,643
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Warrant to Purchase Common Stock
P - Purchase 35,714 35,714
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Warrant to Purchase Common Stock
C - Conversion 3,048 3,048
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1a Warrants
C - Conversion -62,500 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1 Preferred Stock
C - Conversion -555,622 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1c Preferred Stock
C - Conversion -3,571,428 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1b Preferred Stock
C - Conversion -410,000 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1a Preferred Stock
C - Conversion -250,000 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Series 1d Preferred Stock
C - Conversion -302,112 0 -100.00
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
P - Purchase 35,714 35,714
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
C - Conversion 27,103 532,925 5.36
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
C - Conversion 174,216 505,822 52.54
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
C - Conversion 20,000 331,606 6.42
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
C - Conversion 12,195 311,606 4.07
2021-08-17 2021-08-17 4 DRMA Dermata Therapeutics, Inc.
Common Stock
C - Conversion 44,777 299,411 17.58
2021-08-12 3 DRMA Dermata Therapeutics, Inc.
Common Stock
3,658
2021-08-12 3 DRMA Dermata Therapeutics, Inc.
Common Stock
12,195
2021-08-12 3 DRMA Dermata Therapeutics, Inc.
Common Stock
254,634
2021-07-20 2021-07-16 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 10,000 10,000
2021-07-02 2021-06-30 4 ONCT Oncternal Therapeutics, Inc.
Common Stock
S - Sale -3,669 713,152 -0.51 4.75 -17,428 3,387,472
2021-05-27 2021-05-25 4 ONCT Oncternal Therapeutics, Inc.
Stock Options
A - Award 37,500 37,500
2020-07-31 2020-06-11 4/A ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award 22,500 22,500
2020-07-31 2019-09-12 4/A ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award 40,000 40,000
2020-06-12 2020-06-11 4 ONCT Oncternal Therapeutics, Inc.
Stock Options
A - Award -22,500 22,500 -50.00
2020-06-12 2020-06-12 4 BIOC BIOCEPT INC
Common Stock
S - Sale -556 867 -39.07 0.56 -309 481
2020-06-12 2020-06-12 4 BIOC BIOCEPT INC
Common Stock
S - Sale -445 112 -79.89 0.55 -247 62
2020-06-12 2020-06-12 4 BIOC BIOCEPT INC
Common Stock
S - Sale -159 3,477 -4.37 0.56 -89 1,939
2020-06-09 2020-06-05 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 500 500
2020-05-22 2020-05-21 4 ONCT Oncternal Therapeutics, Inc.
Warrants
P - Purchase 8,706 8,706
2020-05-22 2020-05-21 4 ONCT Oncternal Therapeutics, Inc.
Common Stock
P - Purchase 17,412 716,818 2.49
2019-09-16 2019-09-12 4 ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award -40,000 40,000 -50.00
2019-07-01 2019-06-27 4 CNAT Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2019-06-19 2019-06-17 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 500 500
2019-06-19 2019-04-30 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 30,000 30,000
2019-06-11 2019-06-07 4 ONCT GTX INC /DE/
Warrants
A - Award 3,292 3,292
2019-06-11 2019-06-07 4 ONCT GTX INC /DE/
Common Stock
A - Award 18,346 18,346
2019-06-11 2019-06-07 4 ONCT GTX INC /DE/
Common Stock
A - Award 699,406 699,406
2018-07-02 2018-06-29 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 15,000 15,000
2018-06-25 2018-06-21 4 CNAT Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2017-06-26 2017-06-22 4 CNAT Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2017-06-02 2017-05-31 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 15,000 15,000
2017-04-03 2017-03-31 4 BIOC BIOCEPT INC
Employee Stock Option (right to buy)
A - Award 4,166 4,166
2016-10-21 2016-10-19 4 BIOC BIOCEPT INC
Warrant to Purchase Common Stock
P - Purchase 90,909 90,909
2016-10-21 2016-10-19 4 BIOC BIOCEPT INC
Common Stock
P - Purchase 90,909 109,099 499.77 1.10 100,000 120,009
2016-10-21 2016-06-16 4 BIOC BIOCEPT INC
Common Stock
G - Gift 13,334 16,736 391.95
2016-10-21 2016-06-16 4 BIOC BIOCEPT INC
Common Stock
G - Gift -13,334 18,190 -42.30
2016-10-21 3/A BIOC BIOCEPT INC
Common Stock
10,204
2016-06-24 2016-06-23 4 CNAT Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2016-05-05 2016-05-04 4 BIOC BIOCEPT INC
Warrant to Purchase Common Stock
P - Purchase 35,000 35,000
2016-05-05 2016-05-04 4 BIOC BIOCEPT INC
Common Stock
P - Purchase 50,000 138,356 56.59 1.00 50,000 138,356
2016-01-04 2015-12-31 4 BIOC BIOCEPT INC
Stock Option (right to buy)
A - Award 12,500 12,500
2015-11-10 2015-11-09 4 BIOC BIOCEPT INC
Restricted Stock Units
M - Exercise -53,662 0 -100.00
2015-11-10 2015-11-09 4 BIOC BIOCEPT INC
Restricted Stock Units
M - Exercise -10,204 0 -100.00
2015-11-10 2015-11-09 4 BIOC BIOCEPT INC
Common Stock
M - Exercise 53,662 88,356 154.67
2015-11-10 2015-11-09 4 BIOC BIOCEPT INC
Common Stock
M - Exercise 10,204 34,694 41.67
2015-08-25 2015-08-24 4 BIOC BIOCEPT INC
Restricted Stock Units
M - Exercise -14,286 0 -100.00
2015-08-25 2015-08-24 4 BIOC BIOCEPT INC
Common Stock
M - Exercise 14,286 24,490 140.00
2015-06-15 2015-06-11 4 CNAT Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 35,000 35,000
2015-02-18 2015-02-13 4 BIOC BIOCEPT INC
Warrant to Purchase Common Stock
P - Purchase 40,000 40,000
2015-02-18 2015-02-13 4 BIOC BIOCEPT INC
Common Stock
P - Purchase 40,000 94,570 73.30 1.25 50,000 118,212
2014-06-23 2014-06-19 4 CNAT Conatus Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 35,000 35,000
2014-02-24 2014-02-21 4 BIOC BIOCEPT INC
Stock Options (right to buy)
A - Award 53,108 53,108
2014-02-18 2014-02-13 4 BIOC BIOCEPT INC
Stock Options (right to buy)
A - Award 70,000 70,000
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Warrants (right to buy)
J - Other 36,302 36,302
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Warrants (right to buy)
J - Other 22,175 22,175
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Issuer?s repurchase right (obligation to sell)
E - Other -10,204 0 -100.00 4.62 -47,142
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Restricted Stock Units (right to buy)
J - Other 53,662 53,662
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Restricted Stock Units (right to buy)
J - Other 10,204 10,204
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Convertible Notes (right to buy)
C - Conversion -47,181 0 -100.00
2014-02-12 2014-02-10 4 BIOC BIOCEPT INC
Common Stock
C - Conversion 47,181 54,570 638.53 10.00 471,810 545,700
2014-02-04 3 BIOC BIOCEPT INC
Common Stock
10,204
2014-02-04 3 BIOC BIOCEPT INC
Common Stock
7,389
2014-01-10 2014-01-08 4 CNAT Conatus Pharmaceuticals Inc
Stock Option (Right to Buy)
M - Exercise -12,121 0 -100.00
2014-01-10 2014-01-08 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
M - Exercise 12,121 24,242 100.00 0.99 12,000 24,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -10,000 0 -100.00 22.55 -225,500
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -25,000 0 -100.00 23.00 -575,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -25,000 0 -100.00 22.00 -550,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -25,000 0 -100.00 29.00 -725,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -40,000 0 -100.00 25.27 -1,010,800
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -42,000 0 -100.00 26.68 -1,120,560
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -32,000 0 -100.00 28.67 -917,440
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -42,000 0 -100.00 28.88 -1,212,960
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -42,000 0 -100.00 25.27 -1,061,340
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -42,000 0 -100.00 10.07 -422,940
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Common Stock
U - Other -18,000 0 -100.00 32.00 -576,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Common Stock
U - Other -5,000 0 -100.00 32.00 -160,000
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Common Stock
U - Other -164,713 0 -100.00 32.00 -5,270,816
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Common Stock
U - Other -130,739 0 -100.00 32.00 -4,183,648
2013-09-27 2013-09-26 4 CNAT Conatus Pharmaceuticals Inc
Stock Option (Right to Buy)
M - Exercise -12,121 0 -100.00
2013-09-27 2013-09-26 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
M - Exercise 12,121 12,121 2.31 28,000 28,000
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 50,000 50,000
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series A Preferred Stock
C - Conversion -162,356 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
P - Purchase 2,588 143,739 1.83 11.00 28,468 1,581,129
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 261 141,151 0.19 11.00 2,871 1,552,661
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
C - Conversion 19,679 140,890 16.24
2013-07-24 3 CNAT Conatus Pharmaceuticals Inc
Common Stock
121,211
2013-06-12 2013-06-11 4 SNTS SANTARUS INC
Stock Option (right to buy)
A - Award 42,000 42,000
2013-03-08 2013-03-06 4 SOMX Pernix Sleep, Inc.
Common Stock
D - Sale to Issuer -40,098 0 -100.00
2013-03-08 2013-03-06 4 SOMX Pernix Sleep, Inc.
Common Stock
D - Sale to Issuer -70,388 0 -100.00
2013-01-03 2012-12-31 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
A - Award 16,033 70,388 29.50
2012-12-13 2012-12-12 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -42,000 0 -100.00
2012-12-13 2012-12-12 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -42,000 0 -100.00
2012-12-13 2012-12-12 4 SNTS SANTARUS INC
Common Stock
M - Exercise 42,000 304,452 16.00 2.47 103,740 751,996
2012-12-13 2012-12-12 4 SNTS SANTARUS INC
Common Stock
M - Exercise 42,000 262,452 19.05 2.02 84,840 530,153
2012-10-02 2012-09-30 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
A - Award 137,586 434,845 46.28
2012-07-03 2012-07-02 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
A - Award 144,951 297,259 95.17
2012-06-14 2012-06-13 4 SNTS SANTARUS INC
Stock Option (right to buy)
A - Award 42,000 42,000
2012-06-04 2012-05-31 4 SOMX Somaxon Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 40,000 40,000
2012-04-04 2012-04-02 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
A - Award 152,308 152,308
2012-04-04 2011-08-30 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
G - Gift -2,200 320,787 -0.68
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -42,000 0 -100.00
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -32,000 0 -100.00
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -4,285 0 -100.00
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -11,428 0 -100.00
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 2,000 18,000 12.50 5.34 10,675 96,071
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 4,000 16,000 33.33 5.34 21,380 85,520
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 1,000 12,000 9.09 5.34 5,340 64,080
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 2,000 11,000 22.22 5.34 10,676 58,716
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 1,000 9,000 12.50 5.35 5,352 48,172
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 1,000 8,000 14.29 5.35 5,350 42,800
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 5,779 7,000 473.30 5.34 30,880 37,404
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
P - Purchase 1,221 1,221 5.34 6,521 6,521
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
M - Exercise 42,000 220,452 23.54 2.38 99,960 524,676
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
M - Exercise 32,000 178,452 21.85 1.18 37,760 210,573
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
M - Exercise 4,285 146,452 3.01 1.22 5,249 179,404
2012-03-22 2012-03-21 4 SNTS SANTARUS INC
Common Stock
M - Exercise 11,428 142,167 8.74 0.88 10,000 124,396
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00 5.47 -273,500
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -30,000 0 -100.00 4.11 -123,300
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -150,000 0 -100.00 4.34 -651,000
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -30,000 0 -100.00 6.49 -194,700
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -150,000 0 -100.00 7.84 -1,176,000
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -30,000 0 -100.00 8.25 -247,500
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -30,000 0 -100.00 8.67 -260,100
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -70,000 0 -100.00 4.37 -305,900
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -33,333 0 -100.00 2.39 -79,666
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00 6.56 -328,000
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00 2.54 -127,000
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -68,182 0 -100.00 1.10 -75,000
2012-03-09 2012-03-07 4 MITI MICROMET, INC.
Stock Option (right to buy)
D - Sale to Issuer -83,333 0 -100.00 1.10 -91,666
2012-03-06 2012-03-02 4 MITI MICROMET, INC.
Common Stock
U - Other -18,165 0 -100.00 11.00 -199,815
2012-03-06 2012-03-02 4 MITI MICROMET, INC.
Common Stock
U - Other -103,786 0 -100.00 11.00 -1,141,646
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)